References
Bhullar, K. S., Lagaron, N. O., McGowan, E. M., Parmar, I., Jha, A., Hubbard, B. P., & Rupasinghe, H. P. V. (2018). Kinase-targeted cancer therapies: progress, challenges and future directions. Mol Cancer, 17 (1), 48. doi:10.1186/s12943-018-0804-2
Breen, M. E., & Soellner, M. B. (2015). Small molecule substrate phosphorylation site inhibitors of protein kinases: approaches and challenges. ACS chemical biology, 10 (1), 175-189. doi:10.1021/cb5008376
Camidge, D. R., Pao, W., & Sequist, L. V. (2014). Acquired resistance to TKIs in solid tumours: learning from lung cancer. Nat Rev Clin Oncol, 11 (8), 473-481. doi:10.1038/nrclinonc.2014.104
Cho, E. J., Devkota, A. K., Stancu, G., Edupunganti, R., Powis, G., & Dalby, K. N. (2018). A Fluorescence-Based High-Throughput Assay for the Identification of Anticancer Reagents Targeting Fructose-1,6-Bisphosphate Aldolase. SLAS Discov, 23 (1), 1-10. doi:10.1177/2472555217726325
Cox, K. J., Shomin, C. D., & Ghosh, I. (2011). Tinkering outside the kinase ATP box: allosteric (type IV) and bivalent (type V) inhibitors of protein kinases. Future Med Chem, 3 (1), 29-43. doi:10.4155/fmc.10.272
Fabbro, D. (2015). 25 years of small molecular weight kinase inhibitors: potentials and limitations. Mol Pharmacol, 87 (5), 766-775. doi:10.1124/mol.114.095489
Fasano, M., Della Corte, C. M., Califano, R., Capuano, A., Troiani, T., Martinelli, E., . . . Morgillo, F. (2014). Type III or allosteric kinase inhibitors for the treatment of non-small cell lung cancer. Expert Opin Investig Drugs, 23 (6), 809-821. doi:10.1517/13543784.2014.902934
Force, T., & Kolaja, K. L. (2011). Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes. Nat Rev Drug Discov, 10 (2), 111-126. doi:10.1038/nrd3252
Garuti, L., Roberti, M., & Bottegoni, G. (2010). Non-ATP competitive protein kinase inhibitors. Curr Med Chem, 17 (25), 2804-2821. doi:10.2174/092986710791859333
Gross, S., Rahal, R., Stransky, N., Lengauer, C., & Hoeflich, K. P. (2015). Targeting cancer with kinase inhibitors. The Journal of Clinical Investigation, 125 (5), 1780-1789. doi:10.1172/JCI76094
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013). Cancer drug resistance: an evolving paradigm. Nat Rev Cancer, 13 (10), 714-726. doi:10.1038/nrc3599
Hook, K. E., Garza, S. J., Lira, M. E., Ching, K. A., Lee, N. V., Cao, J., . . . Pavlicek, A. (2012). An integrated genomic approach to identify predictive biomarkers of response to the aurora kinase inhibitor PF-03814735. Mol Cancer Ther, 11 (3), 710-719. doi:10.1158/1535-7163.MCT-11-0184
Huang, D., Zhou, T., Lafleur, K., Nevado, C., & Caflisch, A. (2010). Kinase selectivity potential for inhibitors targeting the ATP binding site: a network analysis. Bioinformatics, 26 (2), 198-204. doi:10.1093/bioinformatics/btp650
Kang, M. H., Smith, M. A., Morton, C. L., Keshelava, N., Houghton, P. J., & Reynolds, C. P. (2011). National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing. Pediatr. Blood Cancer, 56 (2), 239-249. doi:10.1002/pbc.22801 [doi]
Kim, Y. H., Girard, L., Giacomini, C. P., Wang, P., Hernandez-Boussard, T., Tibshirani, R., . . . Pollack, J. R. (2006). Combined microarray analysis of small cell lung cancer reveals altered apoptotic balance and distinct expression signatures of MYC family gene amplification.Oncogene, 25 (1), 130-138. doi:10.1038/sj.onc.1208997
Kufareva, I., & Abagyan, R. (2008). Type-II kinase inhibitor docking, screening, and profiling using modified structures of active kinase states. J Med Chem, 51 (24), 7921-7932. doi:10.1021/jm8010299
Mohiuddin, I. S., & Kang, M. H. (2019). DNA-PK as an Emerging Therapeutic Target in Cancer. Front Oncol, 9 , 635. doi:10.3389/fonc.2019.00635
Mohiuddin, I. S., Wei, S. J., & Kang, M. H. (2020). Role of OCT4 in cancer stem-like cells and chemotherapy resistance. Biochim Biophys Acta Mol Basis Dis, 1866 (4), 165432. doi:10.1016/j.bbadis.2019.03.005
Mollaoglu, G., Guthrie, M. R., Bohm, S., Bragelmann, J., Can, I., Ballieu, P. M., . . . Oliver, T. G. (2017). MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition. Cancer Cell, 31 (2), 270-285. doi:10.1016/j.ccell.2016.12.005
Niederst, M. J., & Engelman, J. A. (2013). Bypass mechanisms of resistance to receptor tyrosine kinase inhibition in lung cancer.Sci Signal, 6 (294), re6. doi:10.1126/scisignal.2004652
Owonikoko, T. K., Nackaerts, K., Csoszi, T., Ostoros, G., Baik, C., Mark, Z., . . . Spigel, D. R. (2016). 1423O - Randomized phase 2 study of investigational aurora A kinase (AAK) inhibitor alisertib (MLN8237) + paclitaxel (P) vs placebo + P as second line therapy for small-cell lung cancer (SCLC). Annals of Oncology, 27 , vi493. doi:https://doi.org/10.1093/annonc/mdw389.01
Panicker, R. C., Chattopadhaya, S., Coyne, A. G., & Srinivasan, R. (2019). Allosteric Small-Molecule Serine/Threonine Kinase Inhibitors.Adv Exp Med Biol, 1163 , 253-278. doi:10.1007/978-981-13-8719-7_11
Roskoski, R., Jr. (2020). Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update. Pharmacol Res, 152 , 104609. doi:10.1016/j.phrs.2019.104609
Sos, M. L., Dietlein, F., Peifer, M., Schottle, J., Balke-Want, H., Muller, C., . . . Thomas, R. K. (2012). A framework for identification of actionable cancer genome dependencies in small cell lung cancer.Proc Natl Acad Sci U S A, 109 (42), 17034-17039. doi:10.1073/pnas.1207310109
Tam, W. L., & Weinberg, R. A. (2013). The epigenetics of epithelial-mesenchymal plasticity in cancer. Nat Med, 19 (11), 1438-1449. doi:10.1038/nm.3336
Wei, S. J., Nguyen, T. H., Yang, I. H., Mook, D. G., Makena, M. R., Verlekar, D., . . . Kang, M. H. (2020). MYC transcription activation mediated by OCT4 as a mechanism of resistance to 13-cisRA-mediated differentiation in neuroblastoma. Cell Death Dis, 11 (5), 368. doi:10.1038/s41419-020-2563-4
Wilson, L. J., Linley, A., Hammond, D. E., Hood, F. E., Coulson, J. M., MacEwan, D. J., . . . Prior, I. A. (2018). New Perspectives, Opportunities, and Challenges in Exploring the Human Protein Kinome.Cancer Res, 78 (1), 15-29. doi:10.1158/0008-5472.CAN-17-2291
Zhang, C., Ryu, Y. K., Chen, T. Z., Hall, C. P., Webster, D. R., & Kang, M. H. (2012). Synergistic activity of rapamycin and dexamethasone in vitro and in vivo in acute lymphoblastic leukemia via cell-cycle arrest and apoptosis. Leuk. Res, 36 (3), 342-349. doi:S0145-2126(11)00520-0 [pii];10.1016/j.leukres.2011.10.022 [doi]
Zhang, J., Yang, P. L., & Gray, N. S. (2009). Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer, 9 (1), 28-39. doi:10.1038/nrc2559
Zhang, Y., Chang, F. M., Huang, J., Junco, J. J., Maffi, S. K., Pridgen, H. I., . . . Wei, S. J. (2014). DSSylation, a novel protein modification targets proteins induced by oxidative stress, and facilitates their degradation in cells. Protein Cell, 5 (2), 124-140. doi:10.1007/s13238-013-0018-8